RXRX — Recursion Pharmaceuticals Inc. stock price and chart

Share this page

RXRX

$3.47-16.71%

as of close, Oct 16, 2026

☾ AH $3.47 -16.71%

Recursion Pharmaceuticals Inc.Stock · HealthcareRussell 2000 0.06%Nasdaq Composite 0.006%US Stock Market 0.003%Russell 3000 0.002%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Apr 20, 2021

VolumeEEEE

20212022202420252026

5.010.015.020.025.030.035.040.00200.0M$3.46

2026-10-16

Price$3.46

MA20$3.54

MA50$3.42

Vol122.2M

What would $1,000 invested in RXRX be worth today? →

RXRX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $3.47
YTD price return: -15.28%
YTD total return: -15.28%
Next earnings: Nov 4, 2026
Market cap: 1.9B2021-06 6.1B2026-10 1.9B-69.8% over the window
Enterprise value: 1.4B
Shares outstanding: 535.3M2019-12 21.6M2026-06 535.3M+2381.9% over the window
52W low: $2.77
52W high: $7.18
From 52W high: -51.74%
From 52W low: +25.09%
52W range: 16%

Volume

Rel volume: 1.45×
30D volume: 28M
30D $ vol: 111.9M

Fundamentals

Sales (ttm): 54.9M2019-12 2.3M2026-06 54.9M+2265.5% over the window
Sales/share: $0.102019-12 $0.112026-06 $0.10-4.7% over the window
EPS (ttm): -$1.022019-12 -$2.872026-06 -$1.02-64.4% over the window
FCF (ttm): -352.3M2019-12 -61M2026-06 -352.3M+477.9% over the window
FCF/share: -$0.662019-12 -$2.832026-06 -$0.66-76.7% over the window
Book value/share: $1.712019-12 -$5.762026-06 $1.71-129.7% over the window
Net margin: -945.92%2019-12 -2668.3%2026-06 -945.9%-64.6% over the window
ROE: -56.71%2021-06 -19.3%2026-06 -56.7%+194.5% over the window
ROA: -42.79%2020-12 -29.1%2026-06 -42.8%+46.8% over the window
Debt / equity: 0.01×2021-06 0.022026-06 0.01-73.6% over the window
Current ratio: 5.032020-12 11.532026-06 5.03-56.4% over the window

Growth (CAGR, ttm) · 10Y

Sales: -15.09%2025-06-30 → 2026-06-3064.6M → 54.9M (-15.1% total)+3.15%2023-06-30 → 2026-06-3050M → 54.9M (+9.7% total)+44.11%2021-06-30 → 2026-06-308.8M → 54.9M (+521.4% total)n/a
Shares: +23.70%2025-06-30 → 2026-06-30432.8M → 535.3M (+23.7% total)+37.31%2023-06-30 → 2026-06-30206.7M → 535.3M (+158.9% total)+26.03%2021-06-30 → 2026-06-30168.4M → 535.3M (+217.9% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: -31.36%2025-06-30 → 2026-06-30$0.15 → $0.10 (-31.3% total)-24.88%2023-06-30 → 2026-06-30$0.24 → $0.10 (-57.6% total)+14.35%2021-06-30 → 2026-06-30$0.05 → $0.10 (+95.5% total)n/a
Book value/share: -19.53%2025-06-30 → 2026-06-30$2.12 → $1.71 (-19.5% total)-9.00%2023-06-30 → 2026-06-30$2.27 → $1.71 (-24.7% total)-14.84%2021-06-30 → 2026-06-30$3.82 → $1.71 (-55.2% total)n/a
Price: -45.54%2025-10-16 → 2026-10-16$6.36 → $3.47 (-45.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-19.12%2023-10-16 → 2026-10-16$6.55 → $3.47 (-47.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-28.87%2021-10-15 → 2026-10-16$19.04 → $3.47 (-81.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: -45.54%2025-10-16 → 2026-10-16$6.36 → $3.47 (-45.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-19.12%2023-10-16 → 2026-10-16$6.55 → $3.47 (-47.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-28.87%2021-10-15 → 2026-10-16$19.04 → $3.47 (-81.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -3.4×2021-06 -49.672026-10 -3.57-92.8% over the window
Fwd P/E: -4.8×
P/S (ttm)Market cap ÷ TTM revenue.: 33.8×2021-06 696.452026-10 33.82-95.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 2.0×2021-06 9.562026-10 2.03-78.8% over the window
EV/Sales (ttm): 25.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -18.99%2021-03 -1.3%2026-06 -17.9%+1229.6% over the window
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($-387.8M) ÷ today's market cap ($1.9B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: -20.91%2021-03 0.0%2026-06 -19.7%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $-387.8M + TTM dividends $0) ÷ today's market cap ($1.9B). Same caveat as the cash buyback yield.: -20.91%2021-03 0.0%2026-06 -19.7%

Vs own 10Y history

P/S: 29th
P/B: 15th

Bar = where today’s multiple sits in RXRX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-16.71%

-20.53%

+8.62%

+14.74%

YTD

-15.28%

-45.52%

-81.80%

Financial statements

Open full RXRX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

RXRX — Recursion Pharmaceuticals Inc. price, chart and key statistics